Scientists supercharge natural killer cells to fight aggressive cancers
Scientists have found a way to unleash the immune system’s natural killer cells against some of the toughest cancers yet.
Date: May 24, 2026 Source: McGill University Summary: Scientists at McGill University have found a way to supercharge the immune system’s natural killer (NK) cells, helping them break through the defenses tumors use to stay alive. By temporarily blocking two proteins, researchers turned these cells into far more effective cancer fighters against difficult cancers like leukemia, glioblastoma, kidney cancer, and triple-negative breast cancer. Share: Facebook Twitter Pinterest LinkedIN Email FULL STORY
Scientists have developed a new way to strengthen the cancer-fighting abilities of natural killer (NK) cells, a type of immune cell that serves as one of the body's first defenses against disease. The strategy could help these cells overcome the protective barriers many tumors use to avoid being destroyed.
Researchers at McGill University's Rosalind & Morris Goodman Cancer Institute, working with the Research Institute of the McGill University Health Centre, discovered that blocking two specific proteins dramatically improves the ability of NK cells to attack cancer.
In preclinical studies, the enhanced immune cells successfully killed human cancer cells from several aggressive cancers, including leukemia, glioblastoma, kidney cancer, and triple-negative breast cancer. The treatment approach also significantly slowed tumor growth in animal models.
"This approach is particularly promising for patients who currently have very few options, when standard treatments have failed," said senior author Michel L. Tremblay, Distinguished James McGill Professor in McGill's Department of Biochemistry and researcher at the Rosalind & Morris Goodman Cancer Institute.
New NK Cell Therapy Avoids Permanent Genetic Changes
Many modern cancer immunotherapies rely on genetic engineering to permanently modify immune cells. While effective in some cases, those changes can carry risks because they are difficult to reverse if unintended side effects occur.
The new method takes a different approach. Instead of permanently altering the cells, researchers used small-molecule drugs to temporarily increase NK cell activity. Because the changes are reversible, scientists believe the strategy may offer a safer and more controllable form of immunotherapy.
The team also says the technique could solve some of the practical challenges that have slowed the broader use of cell-based cancer treatments.
Faster and More Affordable Cancer Immunotherapy
The NK cells used in the study came from donated umbilical cord blood. Scientists at the Cellular Therapy Laboratory, led by Pierre Laneuville and Linda Peltier at the Research Institute of McGill University Health Centre, isolated, cultured, and stored the cells so they could potentially be used to treat multiple patients.
This differs from many existing immunotherapies, which often require doctors to collect and customize each patient's own immune cells before treatment. That process can take weeks and is expensive and complex.
"These NK cells can be ready to use immediately," researchers explained, making the therapy potentially faster and easier to deliver.
"This approach will make immunotherapy at McGill University Health Centre faster, safer and more affordable," added Chu-Han Feng, a research scientist at the Rosalind & Morris Goodman Cancer Institute. "It avoids the complex process of customizing cells and uses readily available drugs to reversibly enhance NK cells' anti-tumor activities."
Future Clinical Trials for Aggressive Leukemia
The research team hopes to eventually test the therapy in human clinical trials. One of the first targets could be acute myeloid leukemia, an aggressive blood cancer with limited treatment options for many patients.
The proposed trials are currently awaiting funding and regulatory approval.
Study Details
The study, "PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGF𝛃1 response" by Chu-Han Feng et al. and Michel L. Tremblay, was published in EMBO Reports in April 2026.
Funding for the research was provided by the Canadian Institutes of Health Research Foundation, the McGill University Health Centre Foundation, the Jeanne and Jean-Louis Levesque Foundation, the Richard and Edith Strauss Foundation, the Cedars Cancer Foundation, and Genome Canada/Genome Quebec through a GAPP grant.
The researchers also thanked the mothers who volunteered to donate the cord blood used in the study.
Story Source:
Materials provided by McGill University. Note: Content may be edited for style and length.
Journal Reference:
- Chu-Han Feng, Linda Peltier, Tiffanie Chouleur, Milea DiPonzio, Isabelle Aubry, Alexandre J Poirier, Zuzet M Cordova, Yunyun Shen, Sébastien Tabariès, Xiaona Cao, Guojun Chen, Andreas Bikfalvi, Silvia M Vidal, Peter M Siegel, Pierre Laneuville, Michel L Tremblay. PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses. EMBO Reports, 2026; 27 (10): 2581 DOI: 10.1038/s44319-026-00745-0
Cite This Page:
McGill University. "Scientists supercharge natural killer cells to fight aggressive cancers." ScienceDaily. ScienceDaily, 24 May 2026. <www.sciencedaily.com/releases/2026/05/260523103910.htm>. McGill University. (2026, May 24). Scientists supercharge natural killer cells to fight aggressive cancers. ScienceDaily. Retrieved May 24, 2026 from www.sciencedaily.com/releases/2026/05/260523103910.htm McGill University. "Scientists supercharge natural killer cells to fight aggressive cancers." ScienceDaily. www.sciencedaily.com/releases/2026/05/260523103910.htm (accessed May 24, 2026).Explore More
from ScienceDaily RELATED STORIES This Virus Therapy Supercharges the Immune System Against Brain Cancer Mar. 20, 2026 Scientists have found a way to make one of the most aggressive brain tumors vulnerable to the immune system. A single injection of a modified virus can invade glioblastoma, kill cancer cells, and ... MIT Scientists Strip Cancer of Its Sugar Shield Dec. 23, 2025 Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that ... Blocking One Protein Supercharges the Immune System Against Cancer Oct. 1, 2025 Scientists have found a way to supercharge the immune system’s T cells by blocking a protein called Ant2, essentially rewiring how these cells generate energy. This metabolic reprogramming makes ... Lupus-Related Antibody Shows Promise in Enhancing Cancer Treatment Efficacy Mar. 25, 2025 Scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into 'cold' tumors and flip on an ... Discovery Could Lead to Better Cancer Immunotherapy May 31, 2022 A type of white blood cell previously known only as a helper in the immune system appears also to be the instigator of the body's defenses against cancerous tumors. The discovery could lead to ... Study Reveals How to Activate the Immune System’s Natural Killer Cells to Protect Against Cancer and Other Diseases Mar. 16, 2022 Collagens and elastin in the extracellular matrix, which forms a scaffold to support organs, cause the immune system's natural killer cells to switch off their 'killer' function. The ... TRENDING AT SCITECHDAILY.comSimple Fiber Supplement Cuts Knee Arthritis Pain in Just 6 Weeks, Study Finds
Common Asthma Drug May Reverse Dangerous Fatty Liver Disease
Extra Weight Could Age Your Brain Faster, Study Warns
Scientists Warn: America’s Most Popular Cooking Oil May Be Harming Your Intestines
Схожі новини
Харківському Медіа Хабу 4 роки
Крихітна істота роками залишалася загадкою для науки: дослідники відкрили тваринку розміром з м’яч для гольфу
China launches crewed space flight as part of moon ambitions
